Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Author:
- 10 January 2025
- journal article
- research article
- Published by Springer Nature in Pediatric Drugs
- Vol. 27 (1) , 111-118
Abstract
Oral ganaxolone (ZTALMY®), a synthetic analogue of the endogenous neuroactive steroid allopregnanolone, acts as a positive allosteric modulator of synaptic and extra-synaptic γ-aminobutyric acid (GABA) type A receptor function in the CNS. In the EU and the UK, it is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2–17 years. In a multinational phase III study (Marigold), 17 weeks’ therapy with adjunctive ganaxolone, administered orally three times daily with food, significantly reduced 28-day major motor seizure frequency from baseline versus placebo in patients aged 2–19 years with CDD-associated refractory epilepsy. Antiepileptic efficacy was generally sustained through 2 years of treatment. Ganaxolone was generally well tolerated in Marigold. While somnolence and sedation are related to the dose of ganaxolone, they appear early in treatment and may decrease with continued therapy. Thus, although current evidence is somewhat limited, adjunctive ganaxolone could be a valuable therapeutic option for patients aged 2–17 years with epileptic seizures associated with CDD.Keywords
This publication has 15 references indexed in Scilit:
- Long‐term treatment with ganaxolone for seizures associated with cyclin‐dependent kinase‐like 5 deficiency disorder: Two‐year open‐label extension follow‐upEpilepsia, 2023
- CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging TreatmentCNS Drugs, 2022
- Ganaxolone: First ApprovalDrugs, 2022
- CDKL5 deficiency disorder: clinical features, diagnosis, and managementThe Lancet Neurology, 2022
- A potential new treatment for CDKL5 deficiency disorderThe Lancet Neurology, 2022
- Current neurologic treatment and emerging therapies in CDKL5 deficiency disorderJournal of Neurodevelopmental Disorders, 2021
- Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapyExpert Review of Neurotherapeutics, 2021
- Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to ClinicInternational Journal of Molecular Sciences, 2019
- CDKL5 knockout leads to altered inhibitory transmission in the cerebellum of adult miceGenes, Brain and Behavior, 2016
- Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042; 3α-Hydroxy-3β-methyl-5α-pregnan-20-one), a Selective, High-Affinity, Steroid Modulator of the γ-Aminobutyric AcidA ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 1997